肿瘤微环境内的免疫细胞、PD-1与EGFR-TKIs疗效关系新进展

表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIs)靶向治疗如今成为EGFR基因突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的主导治疗方式,但随着用药时间的延长,大部分患者出现靶向药物的耐药.肿瘤微环境是肿瘤细胞赖以生存和发展的内环境,微环境中调节T(regulatory T,Treg)细胞、树突状细胞、巨噬细胞、成纤维细胞等免疫细胞介导的免疫反应以及程序性死亡受体1(programed cell death protein 1,PD-1)及其配体PD-1L/PD-2L可能参与EGFR-TKIs的耐药形成,现本综述将阐述肿瘤微环境中免疫细胞对EGFR-TKIs靶向治疗疗效相互影响的可能机制,以期寻求新的靶点,进一步提高EGFR-TKIs的抗肿瘤疗效和延长有效时间.

New Progress in the Relationship between Immune Cells,PD-1 in Tumor Microenvironment and the Efficacy of EGFR-TKIs

In recent years, targeted therapy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) is the leading treatment modality for patients with advanced non-small cell lung cancer (NSCLC) and EGFR gene muta-tion. However, with the prolongation of the medication time, most of the patients appeared drug resistance. Tumor microenvi-ronment is the internal environment for the survival and development of tumor cells. The immune response which mediated by immune cells, like regulatory T (Treg), dendritic cells, macrophages, fibroblasts, etc. And the programmed cell death receptor 1 (PD-1) with its ligand PD-1L/PD-2L may participate in the drug resistance of EGFR-TKIs. This review will elaborate the possible mechanism of the interaction of immune cells on EGFR-TKIs in the tumor microenvironment, in order to seek new targets, and further improve the anti-tumor e?cacy and prolong the effective time of EGFR-TKIs.